Beam Therapeutics Inc.
BEAM
$24.62
$0.833.49%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 360.91M | 377.71M | 81.55M | 80.16M | 76.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 360.91M | 377.71M | 81.55M | 80.16M | 76.70M |
| Cost of Revenue | 422.55M | 437.38M | 383.65M | 368.88M | 345.83M |
| Gross Profit | -61.64M | -59.67M | -302.09M | -288.72M | -269.13M |
| SG&A Expenses | 120.05M | 116.81M | 96.24M | 92.64M | 92.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 542.60M | 554.19M | 479.88M | 461.52M | 437.88M |
| Operating Income | -181.69M | -176.49M | -398.33M | -381.36M | -361.18M |
| Income Before Tax | -133.37M | -131.16M | -312.67M | -323.75M | -312.92M |
| Income Tax Expenses | 1.37M | 1.37M | 1.00M | 3.41M | 3.41M |
| Earnings from Continuing Operations | -134.74 | -132.53 | -313.67 | -327.16 | -316.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -134.74M | -132.53M | -313.67M | -327.16M | -316.33M |
| EBIT | -181.69M | -176.49M | -398.33M | -381.36M | -361.18M |
| EBITDA | -160.89M | -156.47M | -379.73M | -364.48M | -345.70M |
| EPS Basic | -1.74 | -1.87 | -4.18 | -4.52 | -4.46 |
| Normalized Basic EPS | -1.09 | -1.08 | -2.88 | -3.20 | -3.05 |
| EPS Diluted | -1.78 | -1.91 | -4.18 | -4.52 | -4.46 |
| Normalized Diluted EPS | -1.11 | -1.10 | -2.88 | -3.20 | -3.05 |
| Average Basic Shares Outstanding | 317.92M | 308.49M | 298.41M | 289.73M | 283.60M |
| Average Diluted Shares Outstanding | 319.76M | 310.34M | 298.41M | 289.73M | 283.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
